San Francisco, CA
Summary
This business leverages artificial intelligence to enhance drug discovery processes, focusing on the development of new small molecule medicines. It operates a pipeline of wholly owned and co-developed assets, supported by significant investments. The company emphasizes the integration of advanced machine learning techniques, particularly convolutional neural networks, with extensive chemical libraries to address complex challenges in drug discovery.
Link
Link